Jun 2026 (Q2 FY26) — Jul 30, 2026
Agios Pharmaceuticals Q2 FY26 — Strong Commercial Performance and Pipeline Advancement
Read the full callAgios Pharmaceuticals (AGIO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Agios Pharmaceuticals earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 44.7 | +259.3% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -247.1 | +773.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -101 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$32.32 +4.36% · +$1.35
Performance −19.7% 1Y
1Y: $40.24 on 14 Oct 2025 → $32.32. High $45.49 (18 Nov 2025), low $22.34 (19 Nov 2025).
- Previous close
- $30.97
- 52-week range
- $22.34 – $45.49
- One year
- −21.89%
Overview
- Symbol
- AGIO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Agios Pharmaceuticals earnings calls (AGIO)
Financials
What the filings say
Net profit, year on year: +10% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 11 | 9 | 12 | 13 | 20 | 21 | 45 |
| Expenses | 112 | 136 | 115 | 140 | 130 | 142 | 131 | 155 |
| Operating profit | -103 | -125 | -107 | -127 | -117 | -122 | -110 | -111 |
| Operating margin | −1146.9% | −1165.3% | −1222.0% | −1020.1% | −907.4% | −608.9% | −530.3% | −247.1% |
| Profit before tax | 1,001 | -105 | — | — | -103 | -109 | — | — |
| Tax rate | 5.3% | 8.4% | — | — | 0.0% | 0.9% | — | — |
| Net profit | 948 | -97 | -89 | -112 | -103 | -108 | -99 | -101 |
| EPS ($ per share) | 16.65 | — | -1.55 | -1.93 | -1.78 | — | -1.69 | -1.69 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | — | — | — | — |
| Reserves | -1,105 | -1,516 | -1,843 | -239 | -471 | -823 | -149 | -562 |
| Total liabilities | 171 | 250 | 453 | 146 | 138 | 126 | 122 | 104 |
| Fixed assets | 24 | 31 | 31 | 29 | 23 | 15 | 12 | 11 |
| Total assets | 858 | 891 | 853 | 1,438 | 1,239 | 937 | 1,663 | 1,297 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -304 | -371 | -291 | -407 | -309 | -296 | -390 | -373 |
| Cash from investing | -274 | 91 | 76 | 1,249 | 243 | 240 | 363 | 377 |
| Cash from financing | 546 | 290 | 262 | -766 | 2 | 5 | 14 | 9 |
| Net cash flow | -32 | 10 | 47 | 76 | -64 | -51 | -12 | 13 |
| Capital expenditure | -7 | -12 | -14 | -6 | -5 | -1 | -2 | -4 |
| Free cash flow | -311 | -383 | -305 | -413 | -314 | -297 | -392 | -377 |
Insider filings
91 filings between Oct 27, 2025 and Aug 4, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$4.76M
41 sales by 8 insiders
98% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 1
- Award — granted as compensation
- 49
- Option exercise — converted options into shares
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Goff Brian | — | $1.69M | Apr 2, 2026 |
| Gheuens Sarah | — | $1.63M | Aug 4, 2026 |
| Milanova Tsveta | — | $353.3K | Apr 2, 2026 |
| Burns James William | — | $344.4K | Apr 2, 2026 |
| Jones Cecilia | — | $334.3K | Apr 2, 2026 |
| Washburn Theodore James Jr. | — | $216.6K | Mar 3, 2026 |
| Viswanadhan Krishnan | — | $185.0K | Apr 2, 2026 |
| Scadden David | — | $8.8K | Nov 12, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 4, 2026 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 plan | 30,000 | $914.4K |
| Jul 8, 2026 | Backstrom Jay T. Director | Award | 1,447 | $0 |
| Jul 1, 2026 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 plan | 4,007 | $150.5K |
| Jul 1, 2026 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 plan | 8,375 | $0 |
| Jun 18, 2026 | Foster-Cheek Kaye I Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | Adams Catherine Owen Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | Ho Maykin Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | Scadden David Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | Smith Cynthia Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | Ballal Rahul D. Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | FOUSE JACQUALYN A Director | Option exercise | 2,816 | $0 |
| Jun 18, 2026 | CAPELLO JEFFREY D Director | Option exercise | 2,816 | $0 |
| Jun 13, 2026 | CAPELLO JEFFREY D Director | Option exercise | 1,976 | $0 |
| Jun 13, 2026 | Adams Catherine Owen Director | Option exercise | 1,976 | $0 |
| Apr 2, 2026 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 plan | 25,528 | $0 |
| Apr 2, 2026 | Burns James William Chief Legal Officer | Sale 10b5-1 plan | 3,280 | $113.8K |
| Apr 2, 2026 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 plan | 3,141 | $109.0K |
| Apr 2, 2026 | Burns James William Chief Legal Officer | Option exercise 10b5-1 plan | 8,500 | $0 |
| Apr 2, 2026 | Gheuens Sarah Chief Medical Officer | Sale 10b5-1 plan | 2,940 | $102.0K |
| Apr 2, 2026 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 plan | 8,500 | $0 |
| Apr 2, 2026 | Viswanadhan Krishnan Chief Corp Dev & Strategy | Option exercise 10b5-1 plan | 8,100 | $0 |
| Apr 2, 2026 | Viswanadhan Krishnan Chief Corp Dev & Strategy | Sale 10b5-1 plan | 2,959 | $102.7K |
| Apr 2, 2026 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 plan | 8,500 | $0 |
| Apr 2, 2026 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 plan | 8,500 | $0 |
| Apr 2, 2026 | Goff Brian Chief Executive Officer | Sale 10b5-1 plan | 6,596 | $228.9K |
| Apr 2, 2026 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 plan | 3,262 | $113.2K |
| Apr 2, 2026 | Goff Brian Chief Executive Officer | Sale 10b5-1 plan | 12,472 | $432.9K |
| Apr 2, 2026 | Goff Brian Chief Executive Officer | Option exercise 10b5-1 plan | 13,500 | $0 |
| Mar 5, 2026 | Viswanadhan Krishnan Chief Corp Dev & Strategy | Sale 10b5-1 plan | 2,959 | $82.3K |
| Mar 5, 2026 | Viswanadhan Krishnan Chief Corp Dev & Strategy | Option exercise 10b5-1 plan | 8,100 | $0 |
| Mar 3, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Sale | 5,272 | $152.3K |
| Mar 2, 2026 | Gheuens Sarah Chief Medical Officer | Option exercise 10b5-1 plan | 4,000 | $0 |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 plan | 1,573 | $45.6K |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 plan | 5,303 | $0 |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 plan | 4,000 | $0 |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 plan | 1,681 | $48.7K |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 plan | 5,666 | $0 |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Option exercise 10b5-1 plan | 2,000 | $0 |
| Mar 2, 2026 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 plan | 1,187 | $34.4K |
| Mar 2, 2026 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 plan | 4,000 | $0 |
| Mar 2, 2026 | Milanova Tsveta Chief Commercial Officer | Sale 10b5-1 plan | 1,681 | $48.7K |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 plan | 594 | $17.2K |
| Mar 2, 2026 | Milanova Tsveta Chief Commercial Officer | Option exercise 10b5-1 plan | 5,666 | $0 |
| Mar 2, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 plan | 798 | $23.1K |
| Mar 2, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 plan | 2,695 | $0 |
| Mar 2, 2026 | Jones Cecilia Chief Financial Officer | Sale 10b5-1 plan | 1,187 | $34.4K |
| Mar 2, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 plan | 727 | $21.1K |
| Mar 2, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 plan | 2,450 | $0 |
| Mar 2, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Sale 10b5-1 plan | 698 | $20.2K |
| Mar 2, 2026 | Washburn Theodore James Jr. Principal Accounting Officer | Option exercise 10b5-1 plan | 2,350 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for AGIOS PHARMACEUTICALS, INC.
Free account. Everything above stays public.
Write why you follow AGIOS PHARMACEUTICALS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading